<DOC>
	<DOCNO>NCT02962960</DOCNO>
	<brief_summary>This study conduct characterize pharmacokinetics , pharmacodynamics , safety , tolerability anifrolumab give via subcutaneous ( SC ) route administration adult Systemic Lupus Erythematosus ( SLE ) subject type I Interferon ( IFN ) test high result active skin manifestation receive Standard Care ( SOC ) treatment . In addition , efficacy anifrolumab SLE skin manifestation characterize .</brief_summary>
	<brief_title>A Study Characterize Pharmacokinetics , Pharmacodynamics , Safety Anifrolumab Adult Type I Interferon Test High Systemic Lupus Erythematosus Subject With Active Skin Manifestations</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Skin Manifestations</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon Type I</mesh_term>
	<criteria>1 . Age 18 70 year 2 . Diagnosis paediatric adult SLE &gt; 24 week fulfil ≥4 11 American College Rheumatology ( ACR ) classification criterion least one : Positive antinuclear antibody ( ANA ) Elevated antidsDNA antibody antiSmith ( antiSm ) antibodies 3 . Interferon high test result 4 . Cutaneous Lupus Erythematosus Disease Area Severity Index ( CLASI ) activity score ≥ 10 5 . Currently receive least 1 follow treatment SLE : • Oral prednisone equivalent ≤40 mg/day minimum 2 week prior sign Informed Consent Form ( ICF ) stable dose least 2 week prior randomization • Any follow medication least 12 week prior sign ICF , stable dos least 8 week prior randomization : ( ) Azathioprine ≤200 mg/day ( ii ) Antimalarials ( eg , chloroquine , hydroxychloroquine , quinacrine ) ( iii ) Mycophenolate mofetil ≤2 g/day mycophenolic acid ≤1.44 g/day ( iv ) Oral , subcutaneous ( SC ) , intramuscular methotrexate ≤25 mg/week ( v ) Mizoribine ≤150 mg/day 6 . Must sign active latent tuberculosis ( TB ) . 7 . Must pregnant breastfeeding . 1 . Active severe unstable neuropsychiatric SLE 2 . Active severe SLEdriven renal disease 3 . Any severe herpes infection time 4 . Hepatitis B Virus ( HBV ) , Hepatitis C Virus ( HCV ) , HIV infection . 5 . Known history primary immunodeficiency ( splenectomy , underlying condition predispose infection 6 . Receipt investigation product within 4 week 5 half life prior sign ICF 7 . History cancer , apart : Squamous basal cell carcinoma skin successfully treat . Cervical cancer situ successfully treat</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>